secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073437
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026
--------------------------------------------------------------------------------

- Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.
- Cash $602.1M as of Dec 31, 2025, up from $302.1M; runway into 3Q 2028.
- WVE-007 obesity: INLIGHT Phase 1 showed fat loss similar to GLP-1 at 240mg; Phase 2a multidose planned 1H 2026.
- WVE-006 for AATD: regulatory engagement for accelerated approval; feedback expected mid-2026; 400mg multidose data in Q1 2026.
- GSK collaboration selected fourth program in Jan 2026; eligible for up to $2.8B milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/0001193125-26-073437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/d103046d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer